Depression Clinical Trial
Official title:
New Non-invasive Brain-computer Interface: Theory, Technology and Application Demonstration - Studies on and Intervention for Depressed People Based on Non-invasive BCI and Application Verification
Major Depressive Disorder (MDD) is a serious mental illness and public health problem that poses threat to both physical and mental health. According to statistics from WHO, it is estimated that more than 350 million people worldwide suffer from depression, with a prevalence rate of 2.1% in China, which is approximately 30 million people. At present, due to the lack of neurobiological markers for screening and diagnosing depression, the identification and diagnosis of MDD are based on the judgment of professional doctors, and the treatment mostly relies on clinical symptoms. In terms of treatment, medication remains the main stream for MDD. Although current methods have certain therapeutic effects, patients still suffer from various side effects and poor cognitive function.In current clinical practice, relying purely on symptomatic diagnosis and treatment is difficult to meet the needs of clinical practice, so there is an urgent need to search for neurobiological markers in depression and develop targeted non-invasive intervention technologies. This study aims to combine advanced brain imaging technology, digital twin-brain models, multi-source information decoding technology, integrated detection and intervention technology. The target is to create two new types of non-invasive BCI systems that can regulate emotions. One is a intervention BCI system for MDD that is suitable for hospital settings with the purpose of precise physical stimulation, and the other one is an ecological BCI system that regulate emotions and intervene with depression which is suitable for both hospital settings and future family environments. This study will collect a comprehensive collection of physiological and biochemical indicators from patients with depression and from healthy control groups, as well as multimodal information such as head surface electroencephalography, MRI, and eye movements under different brain states, to personalize the available BCI information of depression related brain regions, circuits, and networks. The study also tries to explore emotional-interactive games that can intervene with depression and build a game data base that is dedicated to MDD. Other goals include designing and establishing two new types of emotional regulation systems, which are precise external physical stimulation intervention and ecological intervention, constructing a BCI regulation system, and conducting application verification to evaluate the regulation effect.
Status | Recruiting |
Enrollment | 400 |
Est. completion date | July 31, 2027 |
Est. primary completion date | July 31, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - = 12 years old, male or female, right-handed, Han ethnicity - Meets the DSM-5 diagnostic criteria for depression, with HAMD-17 scores greater than 17 and YMRS scores less than 6; - Primary school education or above, able to understand the research content, willing to participate in this study and sign an informed consent form Exclusion Criteria: - Concomitant or previous history of organic brain disease or severe traumatic brain injury, personal or family history of epilepsy; - Severe abnormalities in heart, liver, and kidney function; - Patients with severe physical illnesses; - History of substance dependence or abuse (alcohol, cocaine, drugs, etc.); - Patients with mental disorders caused by organic diseases, drug or alcohol induced mental disorders, and other mental disorders; - Pregnancy or lactation period; - Within six months, physical therapy such as MECT and TMS should be used; - Implants of vegetative nerve stimulation; - Individuals who have implanted electronic or metal instruments (such as pacemakers, defibrillators, stents, orthopedic plates, etc.) and undergo ventriculoperitoneal shunt surgery; - Obvious visual and auditory impairment, unable to cooperate in completing neuropsychological and scale assessments. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Mental Health Center | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Mental Health Center | East China Normal University, Shanghai Jiao Tong University School of Medicine, The Fourth People's Hospital of Chengdu, University of Electronic Science and Technology of China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | EEG power in alpha band between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by EEG at 2 weeks. | 2 weeks | |
Primary | EEG power in beta band between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by EEG at 2 weeks. | 2 weeks | |
Primary | MRI imaging of DLPFC between the depression patient group and healthy controls. | Changes in brain imaging from baseline in multimodal emotional data as assessed by MRI at 2 weeks. | 2 weeks | |
Primary | HbO in fNIRS between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by fNIRS at 2 weeks. | 2 weeks | |
Primary | Hb in fNIRS between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by fNIRS at 2 weeks. | 2 weeks | |
Primary | EEG power in alpha band between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by EEG at 4 weeks. | 4 weeks | |
Primary | EEG power in beta band between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by EEG at 4 weeks. | 4 weeks | |
Primary | MRI imaging of DLPFC between the depression patient group and healthy controls. | Changes in brain imaging from baseline in multimodal emotional data as assessed by MRI at 4 weeks. | 4 weeks | |
Primary | HbO in fNIRS between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by fNIRS at 4 weeks. | 4 weeks | |
Primary | Hb in fNIRS between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by fNIRS at 4 weeks. | 4 weeks | |
Primary | EEG power in alpha band between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by EEG at 8 weeks. | 8 weeks | |
Primary | EEG power in beta band between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by EEG at 8 weeks. | 8 weeks | |
Primary | MRI imaging of DLPFC between the depression patient group and healthy controls. | Changes in brain imaging from baseline in multimodal emotional data as assessed by MRI at 8 weeks. | 8 weeks | |
Primary | HbO in fNIRS between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by fNIRS at 8 weeks. | 8 weeks | |
Primary | Hb in fNIRS between the depression patient group and healthy controls. | Changes from baseline in multimodal emotional data as assessed by fNIRS at 8 weeks. | 8 weeks | |
Primary | The score of HAMD-17 in depression patient group and healthy controls. | Changes from baseline in the score of HAMD-17 at 2 weeks | 2 weeks | |
Primary | The score of HAMD-17 in depression patient group and healthy controls. | Changes from baseline in depression patient group in the score of HAMD-17 at 4 weeks | 4 weeks | |
Primary | The score of HAMD-17 in depression patient group and healthy controls. | Changes from baseline in depression patient group in the score of HAMD-17 at 8 weeks | 8 weeks | |
Secondary | The change in the state of depression in depression patient groups | The state of depression in patient group measured by SDS(0-80) at 2 weeks. | 2 weeks | |
Secondary | The change in the state of agitation in depression patient groups | The state of depression in patient group measured by HCL-32(0-32) at 2 weeks. | 2 weeks | |
Secondary | The change in the state of depression in depression patient groups | The state of depression in patient group measured by SDS(0-80) at 4 weeks. | 4 weeks | |
Secondary | The change in the state of agitation in depression patient groups | The state of depression in patient group measured by HCL-32(0-32) at 4 weeks. | 4 weeks | |
Secondary | The change in the state of depression in depression patient groups | The state of depression in patient group measured by SDS(0-80) at 8 weeks. | 8 weeks | |
Secondary | The change in the state of agitation in depression patient groups | The state of depression in patient group measured by HCL-32(0-32) at 8 weeks. | 8 weeks | |
Secondary | The change in the state of anhedonia in depression patient groups | The state of depression in patient group measured by SHAPS(0-64) at 2 weeks. | 2 weeks | |
Secondary | The change in the state of anhedonia in depression patient groups | The state of depression in patient group measured by SHAPS(0-64) at 4 weeks. | 4 weeks | |
Secondary | The change in the state of anhedonia in depression patient groups | The state of depression in patient group measured by SHAPS(0-64) at 8 weeks. | 8 weeks | |
Secondary | The change in the state of anxiety in depression patient groups | The state of anxiety in patient group measured by different scales including GAD-7(0-56) at 2 weeks. | 2 weeks | |
Secondary | The change in the state of anxiety in depression patient groups | The state of anxiety in patient group measured by different scales including GAD-7(0-56) at 4 weeks. | 4 weeks | |
Secondary | The change in the state of anxiety in depression patient groups | The state of anxiety in patient group measured by different scales including GAD-7(0-56) at 8 weeks. | 8 weeks | |
Secondary | The change in the level of cognitive function in depression patient group | The level of cognitive function in patient group measured by RBANS at 2 weeks. | 2 weeks | |
Secondary | The change in the level of cognitive function in depression patient group | The level of cognitive function in patient group measured by RBANS at 4 weeks. | 4 weeks | |
Secondary | The change in the level of cognitive function in depression patient group | The level of cognitive function in patient group measured by RBANS at 8 weeks. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |